Diagnostics

A major study reveals dropping MMR vaccination rates and a surge in measles, but identifies a key window for pediatricians to prevent missed immunizations.

Known for hair styling, Wavytalk is launching a clinically-tested LED mask. Can this at-home device truly rival professional skincare treatments?

Lantheus sells its legacy SPECT business to fusion-tech firm SHINE, sharpening its focus on high-growth PET diagnostics and next-gen cancer therapies.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

With its acquisition of Lantheus' SPECT business, SHINE Technologies is creating a vertically integrated powerhouse to end isotope shortages.

At CES 2026, PETKIT unveiled an AI ecosystem that turns feeders and litter boxes into health monitors, promising to catch illnesses in pets early.

The strategic separation of MarathonLS into two specialized firms aims to boost growth and service in the competitive life sciences support sector.

Intelligent Bio Solutions raised crucial capital for its fingerprint drug test, but the deal's structure sent shares tumbling amid shareholder dilution fears.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

After a year of major acquisitions and AI-driven innovation, all eyes are on Labcorp's strategic vision for 2026 at the J.P. Morgan Healthcare Conference.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

The med-tech firm has submitted its AI-assisted capsule endoscopy module to the FDA, promising faster, more accurate, and accessible GI disease detection.

With soaring revenue and a landmark FDA approval for its Shield cancer test, Guardant Health's upcoming JPM presentation is poised to define its future.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

A new partnership aims to boost low colorectal cancer screening rates by combining trusted patient education with the promise of simpler blood-based tests.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.